A Phase I Trial of BYL719 Plus Letrozole or Exemestane for Patients With Hormone-Receptor Positive Locally-Advanced Unresectable or Metastatic Breast Cancer
Status: Active, no longer recruiting
Phase of Trial: Phase I
Latest Information Update: 07 Jun 2019
Price : $35 *
At a glance
- Drugs Alpelisib (Primary) ; Exemestane; Letrozole
- Indications Advanced breast cancer
- Focus Adverse reactions
- 03 Jun 2019 Planned End Date changed from 1 May 2019 to 1 May 2020.
- 03 Jun 2019 Planned primary completion date changed from 1 May 2019 to 1 May 2020.
- 01 Jun 2018 Planned End Date changed from 1 May 2018 to 1 May 2019.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History